Rivaroxaban, a new oral factor Xa inhibitor, provides new data on anticoagulation

摘要

Venous and arterial thromboembolic disorders have a significant impact on human morbidity and mortality, and as such, novel therapies for providing thromboprophylaxis remain of immense interest [l]. Numerous anticoagulants are currently available to prevent and treat venous and arterial thromboembolic disorders. For many years, the vitamin K antagonists (VKAs), such as warfarin, were the only type of oral anticoagulation. However, there is marked variation in the therapeutic effects of VKAs, with significant inter- and intra-patient variability in anticoagulation response, thus requiring regular monitoring. Injectable anticoagulants such as heparin are inactivated if taken orally and need to be given paraenterally - thus, they are of limited utility for prolonged therapy. The oral antiplatelets aspirin and clopidogrel have been shown to be much less effective than VKAs for the treatment of venous thrombosis and the prevention of thromboembolic events [2].